Acute Myelogenous Leukemia by Judith E. KarpAcute Myelogenous Leukemia by Judith E. Karp

Acute Myelogenous Leukemia

EditorJudith E. Karp

Paperback | November 9, 2010

Pricing and Purchase Info

$338.96 online 
$375.95 list price save 9%
Earn 1,695 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


This is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML). The focus is on selected critical molecular determinants of AML pathogenesis and pathophysiology and the exploitation of these factors by diverse therapeutic agents and modalities. There is an emphasis throughout on the bidirectional flow of knowledge between the clinical and laboratory arenas.
Title:Acute Myelogenous LeukemiaFormat:PaperbackDimensions:440 pages, 10 × 7.01 × 0.07 inPublished:November 9, 2010Publisher:Humana PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:1617376752

ISBN - 13:9781617376757

Look for similar items by category:


Table of Contents

TABLE OF CONTENTSI. Overview of AML: Francis Giles, MD AndersonII. Molecular Foundations of AML Pathogenesis and PathophysiologyA. Transcriptional Control of Myeloid Differentiation and Transformation: Alan Friedman, Johns Hopkins B. Myelodysplasia-Related AML: Ghulam Mufti, King's College, London, EnglandC. Treatment-Related AML: Michelle LeBeau, University of ChicagoD. DNA Damage and Repair: David Steensma and Scott Kaufmann Mayo ClinicE. Apoptosis: Ruben Mesa and Scott Kaufmann, Mayo ClinicF. Drug Resistance Transporters: Douglas Ross, University of MarylandIII. Translating Biology into Clinical Application A. Impact of Cytogenetics on Clinical Outcome: David Grimwade, Guy's Hospital, London, England B. APL: A Classic Tale of Bench to Bedside: Martin Tallman, Northwestern C. Molecular Therapeutics of AML: Selected Targeted Approaches Overview: Edward Sausville, University of Maryland FLT3: Mark Levis, Johns Hopkins Farnesyltransferase: Jeffrey Lancet, Moffitt (University of South Florida) Modulating Gene Expression as a Therapeutic Approach: Tamer Fandy, Hetty Carraway, Steven Gore, Johns Hopkins Growth Factor-Based Differentiation: William Matsui, Johns HopkinsD. Stem Cell Transplantation: Richard Jones, Johns HopkinsE. Vaccine Development: Ivan Borrello, Johns HopkinsIV. Special ChallengesA. Pediatric AML: Robert Arceci, Johns Hopkins -- pending B. AML in the Elderly: Richard Stone, Dana Farber C. Myeloproliferative Disorders: Jason Gottlib, StanfordD. New Clinical Trials Designs: Elihu Estey, MD Anderson

Editorial Reviews

From the reviews:"...warmly recommend this book as a comprehensive, up-to-date, and detailed yet concise source of information about AML." -The New England Journal of Medicine"Acute Myelogenous Leukemia, edited by Judith E. Karp, MD, of Johns Hopkins University, is a multiauthored textbook directed towards the hematologist managing acute leukemia . . It focuses on new approaches, both practical and theoretical, based on laboratory data as well as clinical studies. . This textbook includes up-to-date, well-referenced chapters . . It is a welcomed edition to provide specific information and reference data for hematologists who specialize in AML management." (Barry Cooper, Baylor University Medical Center Proceedings, Vol. 21 (1), 2008)"The book begins with an overview of the disease and ends with a chapter on some of the particular challenges faced by clinicians . . For clinicians involved in investigation of new agents, there is considerable usefulness . . In Acute Myelogenous Leukemia, the reader will find reviews of some of the newer agents and treatment strategies for this uncommon but devastating disease. In addition, this is a reliable source for thorough and clearly written explanations of the scientific development of these new agents." (Laura C. Michaelis, Journal of the American Medical Association, November, 2007)